Unleash Immuno Oncolytics Overview

  • Year Founded
  • 2015

Year Founded

  • Status
  • Out of Business

  • Employees
  • 4

Employees

  • Latest Deal Type
  • Out of Business

Unleash Immuno Oncolytics General Information

Description

Developer of oncolytic virus immunotherapy products designed to offer a proper immune response to treat cancer. The company's products include UIO-512, which is an oncolytic virus designed for targeting both malignant cells and tumour-associated stromal cells, enabling patients to start cancer treatment more quickly, resulting in a better medical outcome.

Contact Information

Website
www.unleash.bio
Ownership Status
Out of Business
Financing Status
Formerly VC-backed
Corporate Office
  • 4320 Forest Park Avenue
  • Suite 304
  • Saint Louis, MO 63108
  • United States
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Vertical(s)
Life Sciences, Oncology
Corporate Office
  • 4320 Forest Park Avenue
  • Suite 304
  • Saint Louis, MO 63108
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Unleash Immuno Oncolytics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Out of Business 01-Apr-2022 Completed Out of Business
4. Early Stage VC 19-Feb-2018 Completed Generating Revenue
3. Accelerator/Incubator 01-Jan-2017 Completed Startup
2. Seed Round 12-May-2016 Completed Startup
1. University Spin-Out 01-Jan-2015 Completed Startup
To view Unleash Immuno Oncolytics’s complete valuation and funding history, request access »

Unleash Immuno Oncolytics Patents

  • 10

    Total Documents Applications and Grants

  • Total Patents Families

  • 2

    Granted

  • 3

    Pending

  • Expiring in next 12 mo

Unleash Immuno Oncolytics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4590836-A2 Oncolytic adenoviral vector and methods of use Pending 20-Sep-2022
EP-4590836-A4 Oncolytic adenoviral vector and methods of use Pending 20-Sep-2022
US-20260102445-A1 Oncolytic adenoviral vector and methods of use Pending 20-Sep-2022
WO-2024064709-A2 Oncolytic adenoviral vector and methods of use Inactive 20-Sep-2022
WO-2024064709-A3 Oncolytic adenoviral vector and methods of use Inactive 20-Sep-2022 A61K35/761
To view Unleash Immuno Oncolytics’s complete patent history, request access »

Unleash Immuno Oncolytics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Ready to get started?

Request a free trial

Unleash Immuno Oncolytics FAQs

  • When was Unleash Immuno Oncolytics founded?

    Unleash Immuno Oncolytics was founded in 2015.

  • Where is Unleash Immuno Oncolytics headquartered?

    Unleash Immuno Oncolytics is headquartered in Saint Louis, MO.

  • What is the size of Unleash Immuno Oncolytics?

    Unleash Immuno Oncolytics has 4 total employees.

  • What industry is Unleash Immuno Oncolytics in?

    Unleash Immuno Oncolytics’s primary industry is Biotechnology.

  • Is Unleash Immuno Oncolytics a private or public company?

    Unleash Immuno Oncolytics is a Private company.

  • What is Unleash Immuno Oncolytics’s current revenue?

    The current revenue for Unleash Immuno Oncolytics is .

  • How much funding has Unleash Immuno Oncolytics raised over time?

    Unleash Immuno Oncolytics has raised $3.3M.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process